Skip to main content
    G

    GeneDx Holdings Corp. (WGS)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $70.22
    +1.61 (+2.35%)

    Market Cap: $2.05B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(13/20)
    Avg Surprise
    +30.95%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.07
    Range$0.07 - $0.08
    7 analysts
    EPS RevisionsNo revisions (7d)
    1
    7
    30d
    EPS Estimate DriftChange to current
    90d ago$0.12-36.6%
    60d ago$0.10-28.9%
    30d ago$0.07+0.6%
    7d ago$0.07+0.6%
    Current$0.07
    Revenue Consensus
    $123M
    Range$122M - $124M
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.26
    Range$0.15 - $0.45
    7 analysts
    Revenue Consensus
    $135M
    Range$132M - $138M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.26---
    Sep 26EST
    		-$0.07---
    Jun 26
    Reported Aug 3
    		$0.01N/A+105.26%Beat-98.0%
    Mar 26
    Reported May 4
    		$-0.28$-0.05-465.66%Miss-203.7%
    Dec 25
    Reported Feb 23
    		$0.14$0.12+16.67%Beat-78.0%
    Sep 25
    Reported Oct 28
    		$0.49$0.42+16.67%Beat+1125.0%
    Jun 25
    Reported Jul 29
    		$0.50$0.11+354.55%Beat+600.0%
    Mar 25
    Reported Apr 30
    		$0.27$0.09+200.00%Beat+181.8%
    Dec 24
    Reported Feb 18
    		$0.64$0.10+515.00%Beat+192.1%
    Sep 24
    Reported Oct 29
    		$0.04N/A+119.05%Beat+104.9%
    Jun 24
    Reported Jul 30
    		$-0.10N/A+66.67%Beat+94.4%
    Mar 24
    Reported Apr 29
    		$-0.33N/A+50.75%Beat+88.6%
    Dec 23
    Reported Feb 20
    		$-0.69$-0.75+8.00%Beat-176.0%
    Sep 23
    Reported Oct 30
    		$-0.82$-1.31+37.40%Beat+87.7%
    Jun 23
    Reported Aug 8
    		$-1.77$-1.31-35.11%Miss+75.1%
    Mar 23
    Reported May 9
    		$-2.90$-1.48-95.95%Miss+67.2%
    Dec 22
    Reported Mar 14
    		$-0.25$-0.16-56.25%Miss-47.1%
    Sep 22
    Reported Nov 14
    		$-6.65$-5.28-25.95%Miss+58.6%
    Jun 22
    Reported Aug 15
    		$-7.12$-5.61-26.92%Miss-3290.5%
    Mar 22
    Reported May 12
    		$-8.84$-9.24+4.33%Beat-734.0%
    Dec 21
    Reported Mar 14
    		$-0.17$-0.26+34.62%Beat-6983.3%
    Sep 21
    Reported Nov 15
    		$-16.06$-5.28-204.17%Miss-
    Jun 21
    Reported Jul 21
    		$-0.21$0.00N/AMiss-
    Mar 21
    Reported May 24
    		$-1.06$0.00N/AMiss-
    Dec 20
    Reported Mar 30
    		$-0.00$0.00N/AMiss-
    Sep 20
    Reported Nov 16
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio195.06EV/EBITDAN/A
    Price/FCF-27.52xFCF Yield-3.63%
    Profitability
    Profit Margin-23.40%Operating Margin-15.20%
    ROE-40.80%ROIC-23.83%
    Financial Health
    Debt/Equity0.66xInterest CoverageN/A
    Current Ratio3.30xQuick Ratio3.06x
    Trading Statistics
    Beta1.97Avg Volume832.33K
    52-Week High$170.8752-Week Low$32.21

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$69.21
    SMA 20$77.44
    SMA 50$81.89
    SMA 200$75.33
    EMA 10$70.19
    EMA 20$74.63
    EMA 50$77.20
    EMA 200$79.74

    MACD

    Line: -4.95Signal: -3.95Hist: -1.00

    ADX

    ADX: 26.2+DI: 21.5-DI: 27.7

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down92.0
    PSAR$62.01

    Bollinger Bands

    Upper Band$99.93
    Lower Band$54.96
    %B Position5807%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    41.6

    Momentum Oscillators

    Stoch %K20.7
    Stoch %D12.8
    Williams %R-69.9
    ROC (10d)-1.0%
    Momentum-0.74
    CCI (20d)-56.1
    MFI (14d)34.1

    Volatility Measures

    ATR (14d)$5.50(7.8%)
    StdDev (20d)11.24
    Hist Vol71.2%(High)

    Volume Flow

    VWAP$69.76
    OBV6.7M
    AD Line4.7M
    CMF (20d)-0.259

    Volume Metrics

    Avg Vol (20d)834.6K
    Vol Ratio0.9x
    VWMA (20d)$78.95

    Pivot Points

    R3$76.61
    R2$72.97
    R1$70.79
    Pivot Point$67.14
    S1$64.97
    S2$61.32
    S3$59.14

    Advanced Oscillators

    TSI-23.44
    Ultimate Osc46.3
    KST-190.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$114.44M$102.25M$120.99M$116.74M$102.69M$87.11M$95.64M$76.87M$70.51M$62.42M$57.42M$53.30M
    Cost of Revenue$36.20M$34.04M$36.72M$32.22M$31.79M$28.64M$29.43M$29.05M$27.56M$25.01M$26.66M$28.04M
    Gross Profit$78.24M$68.21M$84.27M$84.53M$70.90M$58.48M$66.20M$47.83M$42.95M$37.41M$30.75M$25.26M
    Operating Expenses$95.69M$125.68M$98.50M$87.78M$61.94M$63.03M$57.40M$55.61M$53.53M$51.07M$56.40M$68.23M
    R&D$19.66M$19.80M$24.54M$19.83M$15.08M$12.58M$11.59M$11.66M$10.90M$11.57M$12.25M$14.29M
    SG&A$76.04M$74.59M$46.83M$44.44M$46.86M$50.45M$28.14M$26.92M$26.04M$23.42M$31.89M$26.10M
    Operating Income$-17,455,000$-57,471,000$-14,235,000$-3,251,000$8.96M$-4,551,000$8.81M$-7,780,000$-10,579,000$-13,660,000$-25,643,000$-42,967,000
    Interest Income$-1,185,000$-717,000$-520,000$-562,000$-817,000$-640,000$-698,000$-843,000$-894,000$-597,000$0$1.05M
    Interest Expense$0$6.57M$4.00M$4.14M$0$0$3.39M$579,000$18.78M$6.66M$541,000$0
    Income Before Tax$-18,258,000$-62,419,000$-18,230,000$-7,388,000$10.56M$-6,082,000$5.41M$-8,359,000$-29,363,000$-20,321,000$-26,184,000$-42,458,000
    Income Tax Expense$-518,000$897,000$-564,000$247,000$-246,000$447,000$-24,000$-47,000$-190,000$-82,000$-411,000$-172,000
    Net Income$-17,740,000$-63,316,000$-17,666,000$-7,635,000$10.81M$-6,529,000$5.44M$-8,312,000$-29,173,000$-20,239,000$-25,773,000$-42,286,000
    EBITDA$-10,359,000$-48,328,000$-10,829,000$-352,000$17.57M$236,000$11.67M$-1,587,000$-23,251,000$-14,476,000$-19,112,000$-34,839,000
    EBIT$-17,073,000$-55,137,000$-17,710,000$-6,826,000$11.38M$-5,442,000$6.11M$-7,516,000$-28,469,000$-19,724,000$-25,206,000$-43,511,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about WGS

    News

    GeneDx Holdings (WGS) director receives 1,146 shares at no cash cost

    GeneDx Holdings Corp. director Thomas Fuchs received 1,146 shares of Class A Common Stock from the settlement of Restricted Stock Units (RSUs) on September 17, 2026, at no cash cost. After this transaction...

    Stock Titan•9/18/26•Neutral

    Tax-driven stock sale by GeneDx (WGS) CFO after RSU vesting

    GeneDx Holdings Corp. (WGS) CFO Kevin Feeley exercised 7,197 Restricted Stock Units and subsequently sold 3,728 shares. This sale was explicitly stated to be for covering tax withholding obligations associated...

    Stock Titan•9/18/26•Neutral

    GeneDx (WGS) CEO sells 10,501 shares to cover taxes

    GeneDx Holdings Corp. CEO Katherine Stueland exercised 18,750 Restricted Stock Units (RSUs) and subsequently sold 10,501 shares of Class A Common Stock. These sales were conducted as a "sell to cover" transaction...

    Stock Titan•9/18/26•Neutral

    GeneDx CEO Katherine Stueland sells $1.03m in stock

    GeneDx CEO Katherine Stueland sold 10,501 shares of the company’s Class A Common Stock for over $1 million to cover tax obligations from vested restricted stock units (RSUs). These transactions occurred on September 16...

    Investing.com•9/18/26•Neutral

    GeneDx Director Thomas Fuchs Reports RSU Conversion to 1,146 Shares

    Thomas Fuchs, a director at GeneDx Holdings Corp. (NASDAQ:WGS), converted 1,146 restricted stock units (RSUs) into Class A Common Stock shares on September 17...

    Kalkine Media•9/18/26•Neutral

    WGS Valuation and Fair Value

    P/E
    195.1x
    Forward P/E
    63.3x
    P/FCF
    -27.5x
    P/B
    8.5x
    See GNG's fair value

    WGS Profitability: Margins, ROIC and FCF

    Gross margin
    69.4%
    Operating margin
    -15.2%
    Net margin
    -23.4%
    ROIC
    -23.8%
    ROE
    -40.8%
    FCF margin
    -16.7%
    FCF yield
    -3.6%

    WGS Competitors

    CompanyTicker
    Vericel Corp OrdVCEL
    Select Medical HoldingsSEM
    Viridian Therapeutics IncVRDN
    Fortrea Holdings Inc.FTRE
    BioCryst Pharmaceuticals IncBCRX
    Butterfly Network IncBFLY
    Novavax IncNVAX
    Recursion Pharmaceuticals IncRXRX

    Sector: Healthcare

    WGS Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    WGS Bull Case vs Bear Case

    Bull case

    • WGS beat EPS estimates in 87.5% of its last 8 reported quarters.
    • WGS grew quarterly revenue 11.4% year over year.
    • 100.0% of WGS's analyst ratings are Buy or Strong Buy.

    Bear case

    • WGS trades at 195.1x trailing earnings.
    • WGS has a -23.4% net profit margin.

    WGS Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    107.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 7 down

    Frequently Asked Questions About WGS

    Does WGS pay dividends?

    GeneDx Holdings Corp. (WGS) does not currently pay a regular dividend.

    What is WGS's P/E ratio?

    GeneDx Holdings Corp. has a price-to-earnings (P/E) ratio of 195.06.

    What is WGS's market cap?

    GeneDx Holdings Corp. (WGS) has a market capitalization of $2.05B with a current stock price of $70.22.

    Related stocks

    Sector: Healthcare

    All stocks starting with W

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In